In patients whose melanoma has progressed after treatment with ipilimumab, the monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy[1]. This was suggested by a phase III data presented at the ESMO 2014 Congress in Madrid, Spain. "Previously-treated advanced melanoma patients have limited options," says the study's principal investigator, Professor Jeffrey Weber, Director of the Donald A. Adam ...
via Medindia Health News
More READ 
Lake forest health and fitness http://ift.tt/1vu4zm8
No comments:
Post a Comment